The importance of quality-of-life assessment in the management of patients with multiple sclerosis: Recommendations from the Middle East MS Advisory Group

Neurosciences

Volumn 16, Issue 2, 2011, Pages 109-113

  Al Tahan, Abdel Rahman M ^a   Al Jumah, Mohammed A ^b   Bohlega, Saeed M ^c   Al Shammari, Suhail N ^d   Al Sharoqi, Isa A ^e   Dahdaleh, Maurice P ^f   Hosny, Hassan M ^g   Yamout, Bassem I ^h  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d KUWAIT UNIVERSITY   (Kuwait)

^e Neurology Unit   (Bahrain)

^f Arab Medical Centre   (Jordan)

^g CAIRO UNIVERSITY   (Egypt)

^h AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; NATALIZUMAB;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; DEPRESSION; DISTRESS SYNDROME; FATIGUE; HEALTH CARE ACCESS; HUMAN; MEDICAL DECISION MAKING; MIDDLE EAST; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF LIFE QUESTIONNAIRE; PAIN; PHYSICAL DISABILITY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; SEXUAL DYSFUNCTION; SHORT FORM 36; SOCIAL ISOLATION; SOCIAL SUPPORT; WELLBEING;

DISABILITY EVALUATION; HUMANS; MEDICATION RECONCILIATION; MIDDLE EAST; MULTIPLE SCLEROSIS; PHYSICAL EXAMINATION; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 79953694777     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Barbotte E, Guillemin F, Chau N; Lorhandicap Group. Prevalence of impairments, disabilities, handicaps and quality of life in the general population: a review of recent literature. Bull World Health Organ 2001; 79: 1047-1055.
2. Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG. The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008; 6: 1.
3. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000; 38: 1022-1028.
4. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Mult Scler 2003; 9: 411-419.
5. Wu N, Minden SL, Hoaglin DC, Hadden L, Frankel D. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007; 30: 233-267.
6. Kurktze JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
7. Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with multiple sclerosis. Disabil Rehabil 2001; 23: 597-603.
8. Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122: 141-159.
9. Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group. Can J Neurol Sci 1998; 25: 31-38.
10. Isaksson AK, Ahlstrom G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 64-69.
11. Janardhan V, Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 2000; 57: 1485-1491.
12. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004; 97: 671-676.
13. Wynia K, Middel B, van Dijk JP, De Keyser JH, Reijneveld SA. The impact of disabilities on quality of life in people with multiple sclerosis. Mult Scler 2008; 14: 972-980.
14. Grasso MG, Clemenzi A, Tonini A, Pace L, Casillo P, Cuccaro A, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler 2008; 14: 506-513.
15. Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001; 7: 231-235.
16. Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 2008; 14: 1131-1136.
17. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-566.
18. Kern S, Schrempf W, Schneider H, Schultheiss T, Reichmann H, Ziemssen T. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler 2009; 15: 752-758.
19. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76: 469-475.
20. Morales-Gonzales JM, Benito-Leon J, Rivera-Navarro J, Mitchell AJ; GEDMA Study Group. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult Scler 2004; 10: 47-54.
21. D'Alisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A. Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 2006; 28: 307-314.
22. Buchanan RJ, Zhu L, Schiffer R, Radin D, James W. Ruralurban analyses of health-related quality of life among people with multiple sclerosis. J Rural Health 2008; 24: 244-252.
23. Shevil E, Finlayson M. Perceptions of persons with multiple sclerosis on cognitive changes and their impact on daily life. Disabil Rehabil 2006; 28: 779-788.
24. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72: 1760-1765.
25. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003; 9: 63-72.
26. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 1580-1583.
27. Janse AJ, Gemke RJ, Uiterwaal CS, van der Tweel I, Kimpen JL, Sinnema G. Quality of life: patients and doctors don't always agree: a meta-analysis. J Clin Epidemiol 2004; 57: 653-661.
28. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003; 25: 1291-1303.
29. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72: 1760-1765.
30. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003; 74: 710-714.
31. Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler 1999; 5: 317-322.
32. Gruenewald DA, Higginson IJ, Vivat B, Edmonds P, Burman RE. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler 2004; 10: 690-704.
33. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.
34. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999; 5: 251-259.
35. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-973.
36. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-139.
37. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15: 247-258.
38. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 2002; 73: 701-704.
39. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler 2008; 14: 219-230.
40. Miller DM, Kinkel RP. Health-related quality of life assessment in multiple sclerosis. Rev Neurol Dis 2008; 5: 56-64.
41. Lily O, McFadden E, Hensor E, Johnson M, Ford H. Diseasespecific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12: 808-813.
42. Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15 years follow-up study. Mult Scler 2010; 16: 588-596.
43. Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes 2010: 8: 133.
44. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 69-77.
45. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-346.
46. Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes 2005; 3: 16.
47. Vickrey BG. Getting oriented to patient-oriented outcomes. Neurology 1999; 53: 662-663.
48. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000; 68: 144-149.